Based in Gosselies, Belgium, iTeos, a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL), is focused on expanding the benefits of immunotherapy for cancer patients. The Company is developing a proprietary pipeline targeting A2A, immune checkpoints and non-inflamed tumors. It has licensed its IDO1 program, now in Phase 1 development, to Pfizer. iTeos’ competitive edge is in the combination of expertise in drug discovery and translational tumor immunology. The Company uses a unique platform to identify rational combinations of immunotherapies and novel targets. iTeos is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information please visit www.iteostherapeutics.com.